Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.980
-0.120 (-2.35%)
At close: Mar 12, 2026, 4:00 PM EDT
5.05
+0.07 (1.41%)
After-hours: Mar 12, 2026, 5:48 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$1,004,789
Market Cap
364.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | 41 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| Absci | 157 |
| X4 Pharmaceuticals | 143 |
| Niagen Bioscience | 117 |
| Aura Biosciences | 109 |
| Neurogene | 107 |
| Immuneering | 54 |
| NovaBridge Biosciences | 32 |
CADL News
- 10 hours ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 days ago - Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 10 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - GlobeNewsWire
- 20 days ago - Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus - Benzinga
- 20 days ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 21 days ago - Candel Therapeutics Announces Proposed $100 Million Public Offering - GlobeNewsWire
- 21 days ago - Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire